SCHEMBL26110467

SCHEMBL26110467

CC(C)(C)[Si](C)(C)OCC1OC(n2cnc3c(NC(=O)c4ccccc4)ncnc32)C(O[Si](C)(C)C(C)(C)C)C1O[N+](=O)[O-]

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT6 Q96LA8 1/20 0.46
▸ P2RY12 Q9H244 7/20 0.43
▸ P2RY2 P41231 1/20 0.41
▸ P2RY1 P47900 1/20 0.41
▸ P2RY6 Q15077 1/20 0.41
▸ BMPR1B O00238 1/20 0.41
▸ DNPH1 O43598 1/20 0.40
▸ PRKAB2 O43741 1/20 0.40
▸ PRKAG1 P54619 1/20 0.40
▸ PRKAA2 P54646 1/20 0.40
▸ PRKAA1 Q13131 1/20 0.40
▸ PRKAG3 Q9UGI9 1/20 0.40
▸ PRKAG2 Q9UGJ0 1/20 0.40
▸ PRKAB1 Q9Y478 1/20 0.40
▸ ADORA1 P30542 2/20 0.40
▸ P2RX3 P56373 1/20 0.40
▸ P2RX4 Q99571 1/20 0.40
▸ P2RX2 Q9UBL9 1/20 0.40
▸ ADORA3 P0DMS8 1/20 0.40
▸ ADORA2A P29274 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26110462 1.00 PRMT6 (0.46) PRMT6P2RY12P2RY2P2RY1P2RY6
SCHEMBL22206844 0.93 PRMT6 (0.50) PRMT6P2RY12P2RY2P2RY1P2RY6
SCHEMBL26107926 0.91 PRMT6 (0.46) PRMT6P2RY12P2RY2P2RY1P2RY6
SCHEMBL26112399 0.90 PRMT6 (0.48) PRMT6P2RY12P2RY2P2RY1P2RY6
SCHEMBL30586895 0.89 PRMT6 (0.57) PRMT6P2RY12P2RY2P2RY1P2RY6
SCHEMBL26109827 0.89 PRMT6 (0.47) PRMT6P2RY12P2RY2P2RY1P2RY6
SCHEMBL26109690 0.88 PRMT6 (0.48) PRMT6P2RY12P2RY2P2RY1P2RY6
SCHEMBL26109806 0.88 PRMT6 (0.47) PRMT6P2RY12P2RY2P2RY1P2RY6
SCHEMBL26108971 0.88 PRMT6 (0.52) PRMT6P2RY12P2RY2P2RY1P2RY6
SCHEMBL26107628 0.88 PRMT6 (0.53) PRMT6P2RY12P2RY2P2RY1P2RY6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250207163-A1 METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS TRILINK BIOTECHNOLOGIES, LLC 2025-06-26 — — US disclosed
WO-2023183569-A1 METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS Molecular Assemblies, Inc. (US) 2023-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250207163-A1 METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS RNGTT, POLRMT, POLN PRMT6 2509/4885P2RY12 3422/4885P2RY2 3188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback